↓ Skip to main content

Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease

Overview of attention for article published in Cochrane database of systematic reviews, October 2014
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (53rd percentile)

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
56 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease
Published in
Cochrane database of systematic reviews, October 2014
DOI 10.1002/14651858.cd007744.pub2
Pubmed ID
Authors

Xin-Pu Miao, Jian-Sheng Li, Qin Ouyang, Ren-Wei Hu, Yan Zhang, Hui-Yan Li

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to reduce inflammatory pain and swelling in inflammatory bowel disease (IBD) patients with rheumatological manifestations. While these drugs effectively reduce musculoskeletal pain and stiffness, long-term use is limited by gastrointestinal (GI) adverse effects (AEs) and disease exacerbation. As an alternative to NSAIDs, selective cyclooxygenase 2 (COX-2) inhibitors were developed to improve GI safety and tolerability. COX-2 inhibitors include drugs such as celecoxib, rofecoxib, valdecoxib, etoricoxib, and lumiracoxib. Rofecoxib and valdecoxib have been withdrawn from the market worldwide due to safety concerns (most importantly for cardiovascular adverse events) and lumiracoxib has been withdrawn in many countries due to liver toxicity. However, celecoxib and etoricoxib continue to be available for use in many countries. Several studies have examined whether COX-2 inhibitors can be safely used for the treatment of rheumatological manifestations of IBD with inconsistent results. Some investigators report acceptable safety profiles associated with these drugs while others found that COX-2 inhibitors are associated with high rates of disease exacerbation.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 4%
Unknown 54 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 13 23%
Researcher 12 21%
Student > Ph. D. Student 8 14%
Unspecified 6 11%
Student > Bachelor 5 9%
Other 12 21%
Readers by discipline Count As %
Medicine and Dentistry 25 45%
Unspecified 9 16%
Nursing and Health Professions 6 11%
Agricultural and Biological Sciences 4 7%
Psychology 3 5%
Other 9 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 August 2019.
All research outputs
#7,766,421
of 13,481,034 outputs
Outputs from Cochrane database of systematic reviews
#8,469
of 10,617 outputs
Outputs of similar age
#101,989
of 232,443 outputs
Outputs of similar age from Cochrane database of systematic reviews
#211
of 246 outputs
Altmetric has tracked 13,481,034 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 10,617 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.0. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 232,443 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 246 others from the same source and published within six weeks on either side of this one. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.